<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594880</url>
  </required_header>
  <id_info>
    <org_study_id>DAIDS-ES 10401</org_study_id>
    <secondary_id>U01AI065279</secondary_id>
    <nct_id>NCT00594880</nct_id>
  </id_info>
  <brief_title>Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection</brief_title>
  <official_title>Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Wistar Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Wistar Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180
      ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART
      (antiretroviral therapy) interruption in HIV positive, ART-suppressed subjects (viral load
      &lt;50 copies/ml) as determined by observing the percentages of viral load measurements &lt;400
      copies/ml between the two arms over a 24-week period, corresponding to the Pegasys
      monotherapy period (exclusive of dual ART/Pegasys 5-week period). Primary analysis will be an
      &quot;intent to treat&quot; analysis and will address the hypothesis that two different doses of
      Peg-INF-α-2A (90 and 180 ug/week) will be similarly effective at inhibiting viral
      replication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The high toxicity of current Anti-Retroviral Therapy (ART) regimens has driven a number of
      studies investigating therapeutic approaches aimed at reducing drug exposure while
      maintaining the beneficial effects of immune reconstitution. Preliminary observations in
      HCV/HIV co-infected individuals already support an antiviral effect by Pegylated
      Interferon-Alpha-2A (Peg-IFN-Alpha-2A:Pegasys®) on HIV-1 replication; however, the ability of
      Peg-IFN-Alpha-2A (as a single agent) to maintain long-term suppression of HIV-1 replication
      in patients who interrupt ART after having achieved immune reconstitution remains
      undetermined. The rationale for addressing two doses of Peg-IFN-Alpha-2A (180 and 90 ug/week)
      is based on the antiviral activity reported with both doses and the lower incidence of
      adverse events associated with doses lower than that approved for HCV therapy (90 versus
      180ug/week).

      The long-range goal of this proposal is to determine if Peg-IFN-Alpha-2A monotherapy can
      sustain HIV-1 suppression in the absence of ART in infected individuals. Our short-range goal
      is to determine the safety, viral suppressive potential and immune correlates of
      Peg-IFN-Alpha-2A administered upon the cessation of suppressive ART.

      Based on the current literature and our preliminary studies, we hypothesize that weekly doses
      of 90 or 180 ug/wk of Peg-IFN-Alpha-2A administered to pharmacologically-suppressed
      HIV-infected individuals in the course of antiretroviral therapy (ART) discontinuation will
      result in equivalent frequency of viral control, with the lower dose resulting in measurably
      lower rate and intensity of therapy-related adverse events (AE).

      We propose to compare two different doses of Peg-IFN-Alpha-2A (90 or 180 ug/wk) as a
      simplification step to ART, for their ability to maintain viral load suppression when
      initiated 5 weeks before ART interruption in HIV-infected, ART-suppressed patients (VL&lt;50
      copies/ml). Briefly, control will be determined by the the percentages of viral load
      measurements &lt;400 copies/ml between the two arms over a period of 24 weeks, corresponding to
      the Pegasys monotherapy period (exclusive of dual ART/Pegasys 5-week period). A threshold of
      400 is used based on the known potential for blipping on ART between 50 and 400 copies/ml
      with no clinical consequence to sustained suppression thereafter (JAMA 2005, 293:817-829).
      Primary analysis will be an &quot;intent to treat&quot; analysis and will address the hypothesis that
      two different doses of Peg-IFN-Alpha-2A (90 and 180 ug/week) will be similarly effective at
      inhibiting viral replication.

      The secondary objectives of the research are:

        1. To prospectively evaluate dose-dependent, treatment-associated toxicity, safety and
           tolerability of 29 weekly doses of Peg-IFN-Alpha-2A at 180 ug or 90 ug/week (in
           association with ART for the initial 5 weeks, followed by 24 weeks of Peg-IFN-Alpha-2A
           in the absence of ART).

        2. To determine innate immunity outcomes correlated to Peg-IFN-Alpha-2A dose and antiviral
           activity by monitoring Natural Killer (NK) and Dendritic cell (DC) subsets changes and
           the ability to maintain innate immune function (DC secretory responses, NK antiviral
           cytotoxic responses)

        3. To determine adaptive immunity outcomes correlated to Peg-IFN-Alpha-2A dose and
           antiviral activity by monitoring T-cell subsets changes and the ability to maintain
           cell-mediated proliferative and cytokine responses against recall antigens (anti-HIV-1
           gag p55).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Load &lt; 400 Copies/ml</measure>
    <time_frame>12 weeks</time_frame>
    <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load &lt; 48 Copies/ml</measure>
    <time_frame>12 weeks</time_frame>
    <description>% of individuals maintaining VL &lt; 48 copies/ml while on pegylated interferon alpha-2a treatment without ART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load &lt; 400 Copies/ml</measure>
    <time_frame>24 weeks</time_frame>
    <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Pegasys 180 mcg/week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys 90 mcg/week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha 2a, 180 mcg/week sc</intervention_name>
    <description>Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
    <arm_group_label>Pegasys 180 mcg/week</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha 2a, 90 mcg/week sc</intervention_name>
    <description>Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
    <arm_group_label>Pegasys 90 mcg/week</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ≥ 18 but &lt;65 years

          -  Able and willing to provide informed consent.

          -  HIV-1 infection documented by any licensed enzyme-linked immunosorbent assay (ELISA)
             test kit and confirmed by Western Blot at any time prior to or at study entry. HIV-1
             culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other
             than ELISA is acceptable as an alternative confirmatory test

          -  HIV RNA &lt; 75 copies/ml on a regimen of a) 2 Nucleoside Reverse Transcriptase
             Inhibitors (NRTIs) and 1 non-nucleoside RTI (NNRTI) OR b) 2 NRTIs and Protease
             Inhibitor (PI) for at least 24 weeks OR c) 3 NRTIs

          -  HIV RNA &lt; 75 copies/ml at screening

          -  &gt; 6 months ≥ 400 CD4+ T cells/mm3 (CD4 nadir ≥ 200 cells)

          -  Female subjects with childbearing potential: negative pregnancy test (Beta human
             horionic gonadotropin (HCG)). Must agree to use appropriate contraceptive methods
             (barrier devices such as diaphragms or condoms + spermicidal or intrauterine device
             (IUD) or oral contraceptives) while on study.

          -  Karnofsky performance scale score of 80% or better

          -  Willing to adhere to the treatment and schedule approved by the study investigators in
             conjunction with the patient's primary provider.

          -  Willing to abstain from immunomodulatory drugs during the study period, with the
             exception of the study drug (Pegasys®).

          -  Patient Health Questionnaire (PHQ)-2 score &lt; 2, OR PHQ-9 score&lt; 10, OR PHQ-9 score
             10-14 AND medical provider's favorable opinion. In either case, score for PHQ-9
             question # 9 (suicidal ideation) must be 0.

          -  Thyroid stimulating hormone (TSH) within normal range, unless accompanied by thyroid
             profile consistent with normal thyroid function

          -  A negative cardiac stress test if &gt;45yrs men/&gt;55yrs women years of age or if below
             these years of age but with two added risk factors for coronary artery disease
             [smoking, hypertension (BP &gt;140/90 or on antihypertensive medications), low Hight
             density lipoprotein (HDL)-associated cholesterol (&lt;40 mg/dL), family history of
             premature Coronary heart disease (CHD) (&lt;55 yrs males/&lt;65 females)] or a Framingham
             score &gt; 15% (men) or 10% (women))

        Exclusion Criteria:

          -  Currently pregnant or breast feeding.

          -  CD4 cell count &lt; 400 or recorded CD4 nadir &lt; 200 cells/mm3

          -  History of immunomodulatory therapy for over 2 weeks during the 6 months prior to
             enrollment, including, but not limited to: IFN-Alpha or Beta (recombinant or
             pegylated), systemic corticosteroids; systemic cancer chemotherapy/irradiation;
             cyclosporin; tacrolimus (FK-506); OKT-3; any Interleukin, including IL-2;
             cyclophosphamide; methotrexate; IVIG (gamma globulin); G/M-CSF; hydroxyurea;
             thalidomide; pentoxifylline; thymopentin; thymosin; dithiocarbonate;
             polyribonucleoside.

          -  Significant co-existing medical conditions including: Anemia (Hgb &lt;9.1 men, &lt;8.9
             women), Neutropenia (ANC &lt; 1000), Thrombocytopenia (platelet count &lt;50K), Liver
             disease (AST/ALT &gt; 5x, Total Bilirubin &gt; 1.5x upper limits of normal, or Total
             Bilirubin &gt;3x upper limit of the norm (ULN) if receiving indinavir), Renal disease
             (creatinine &gt; 2x upper normal limits), or other conditions, such as active
             drug/alcohol abuse or dependence which would interfere with study compliance.

          -  Any history of heart attacks, myocardial infarction or coronary arterial disease
             (MI/CAD). .

          -  Prior history of major depression or other severe psychiatric disorder/condition
             requiring treatment and/or hospitalization

          -  PHQ-9 score &gt;14, OR PHQ-9 score &gt; 10 - 14 and lack of medical provider's favorable
             opinion, or score for PHQ-9 answer # 9 (suicidal ideation) &gt; 0.

          -  Evidence of chronic active Hepatitis B infection (Surface Antigen HBsAg) or Hepatitis
             C plymerase chain reaction (PCR) positivity at screening (cleared of HCV at entry &gt;6
             months).

          -  Past evidence of medical conditions associated with chronic liver disease including
             genetic hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin
             exposures etc.

          -  History of neutropenia or other hematological abnormalities

          -  Type I diabetes mellitus, or type II diabetes mellitus that is not controlled with
             oral agents and/or insulin.

          -  Ongoing treatment with Isoniazide, Pyrazinamide, Rifabutin, Rifampicin, Diadenosine
             Ganciclovir, Valganciclovir, Oxymetholone, Thalidomide or Theophylline.

          -  History of autoimmune processes including Crohn's disease, ulcerative colitis, severe
             psoriasis, rheumatoid arthritis, myositis, hepatitis etc.

          -  History of major organ transplantation with an existing functional graft.

          -  Active coronary artery disease within 24 weeks prior to study

          -  Hemoglobinopathies such as sickle cell anemia or Thalassemia major.

          -  Hypersensitivity to Pegasys®or any of its components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Montaner, DVM, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Wistar Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Kostman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn-Presbyterian Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Tebas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karam Mounzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonathan Lax Immune Disorders Clinic- Philadelphia FIGHT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn-Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wistar Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonathan Lax Immune Disorders Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26.</citation>
    <PMID>23105144</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>January 24, 2013</results_first_submitted>
  <results_first_submitted_qc>January 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2015</results_first_posted>
  <last_update_submitted>January 28, 2015</last_update_submitted>
  <last_update_submitted_qc>January 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Wistar Institute</investigator_affiliation>
    <investigator_full_name>Luis Montaner</investigator_full_name>
    <investigator_title>Protocol Chair / Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Peg-IFN-Alpha-2A</keyword>
  <keyword>Viral Suppression</keyword>
  <keyword>ART cessation</keyword>
  <keyword>Immune function</keyword>
  <keyword>Innate Immunity</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Immune-based therapy</keyword>
  <keyword>Treatment interruption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>locations: medical clinics (Hospital of the University of Pennsylvania, Jonathan Lax clinic, Drexel University Hospital) Recruitment period: may 8, 2008 to May 27, 2010</recruitment_details>
      <pre_assignment_details>subjects were randomized to the pegasys dose of 180 or 90 mcg/week four weeks after enrollment (week 0: eligibility determination; week 4: enrollment; week 8: randomization and treatment initiation; week 13: ART interruption; week 25: primary endpoint; week 37: secondary endpoints)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegasys 180 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
Pegylated Interferon-alpha 2a, 180 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
        <group group_id="P2">
          <title>Pegasys 90 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
Pegylated Interferon-alpha 2a, 90 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegasys 180 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
Pegylated Interferon-alpha 2a, 180 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
        <group group_id="B2">
          <title>Pegasys 90 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
Pegylated Interferon-alpha 2a, 90 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" lower_limit="42.8" upper_limit="48.5"/>
                    <measurement group_id="B2" value="44" lower_limit="32" upper_limit="49.5"/>
                    <measurement group_id="B3" value="45" lower_limit="40.5" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Viral Load &lt; 400 Copies/ml</title>
        <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
        <time_frame>12 weeks</time_frame>
        <population>excluded 2 withdrawal of consent and 1 lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Pegasys 180 mcg/Week</title>
            <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
Pegylated Interferon-alpha 2a, 180 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
          </group>
          <group group_id="O2">
            <title>Pegasys 90 mcg/Week</title>
            <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
Pegylated Interferon-alpha 2a, 90 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load &lt; 400 Copies/ml</title>
          <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
          <population>excluded 2 withdrawal of consent and 1 lost to follow-up</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load &lt; 48 Copies/ml</title>
        <description>% of individuals maintaining VL &lt; 48 copies/ml while on pegylated interferon alpha-2a treatment without ART</description>
        <time_frame>12 weeks</time_frame>
        <population>% of subjects maintaining VL &lt; 48 copies/ml after 12 weeks of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>180 mcg/Week</title>
            <description>Patients receiving 180 micrograms/week of pegylated interferon alpha-2a</description>
          </group>
          <group group_id="O2">
            <title>90 mcg/Week</title>
            <description>Patients receiving 90 micrograms/week of pegylated interferon alpha-2a</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load &lt; 48 Copies/ml</title>
          <description>% of individuals maintaining VL &lt; 48 copies/ml while on pegylated interferon alpha-2a treatment without ART</description>
          <population>% of subjects maintaining VL &lt; 48 copies/ml after 12 weeks of treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load &lt; 400 Copies/ml</title>
        <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
        <time_frame>24 weeks</time_frame>
        <population>percent of consenting eligible participants (n=8) with VL &lt; 400 at week 24 of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>180 mcg/Week</title>
            <description>Arm 1 subjects with VL &lt; 400 at week 12 of treatment who elected to continue study treatment for an additional 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>90 mcg/Week</title>
            <description>Arm 2 subjects with VL &lt; 400 at week 12 of treatment who elected to continue study treatment for an additional 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load &lt; 400 Copies/ml</title>
          <description>% of individuals maintaining viral suppression (VL &lt; 400 copies/ml) as compared to the anticipated rate of viral suppression in individuals interrupting ART without interferon (9%)</description>
          <population>percent of consenting eligible participants (n=8) with VL &lt; 400 at week 24 of treatment</population>
          <units>percentage of eligible participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pegasys 180 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
Pegylated Interferon-alpha 2a, 180 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
        <group group_id="E2">
          <title>Pegasys 90 mcg/Week</title>
          <description>ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
Pegylated Interferon-alpha 2a, 90 mcg/week sc : Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL &lt; 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver toxicity</sub_title>
                <description>elevated ALT (grade 3 ACTG)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>based on PHQ2/9 questionnaire self evaluatiuon</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The follwing limitations of this study should be noted:
Small number of participants enrolled
Lack of a control arm interrupting ART without immunotherapy</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Luis Montaner</name_or_title>
      <organization>the Wistar Institute</organization>
      <phone>215 898 3934</phone>
      <email>montaner@mail.wistar.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

